CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: VASCULITIS TREATMENT MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Biologics
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Corticosteroids and immunosuppressants
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: VASCULITIS TREATMENT MARKET, BY DISEASE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Small and medium vessel vasculitis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Small and medium vessel vasculitis Vasculitis Treatment Market by Type
5.2.4.1 ANCA associated vasculitis Market size and forecast, by region
5.2.4.2 Others Market size and forecast, by region
5.3 Large vessel vasculitis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: VASCULITIS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Disease Type
7.2.3.1 North America Small and medium vessel vasculitis Vasculitis Treatment Market by Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Disease Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Disease Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Disease Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Disease Type
7.3.3.1 Europe Small and medium vessel vasculitis Vasculitis Treatment Market by Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Disease Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Disease Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Disease Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Disease Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Disease Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Disease Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Disease Type
7.4.3.1 Asia-Pacific Small and medium vessel vasculitis Vasculitis Treatment Market by Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Disease Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Disease Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Disease Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Disease Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Disease Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Disease Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Disease Type
7.5.3.1 LAMEA Small and medium vessel vasculitis Vasculitis Treatment Market by Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Disease Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Disease Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Disease Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Disease Type
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Amneal Pharmaceuticals, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AstraZeneca plc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 F. Hoffmann-La Roche Ltd
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Pfizer Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 InflaRx N.V
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 ChemoCentryx
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 AbbVie
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. VASCULITIS TREATMENT MARKET, FOR BIOLOGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. VASCULITIS TREATMENT MARKET FOR BIOLOGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. VASCULITIS TREATMENT MARKET, FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. VASCULITIS TREATMENT MARKET FOR CORTICOSTEROIDS AND IMMUNOSUPPRESSANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 7. VASCULITIS TREATMENT MARKET, FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. VASCULITIS TREATMENT MARKET FOR SMALL AND MEDIUM VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. GLOBAL SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 10. VASCULITIS TREATMENT MARKET, FOR ANCA ASSOCIATED VASCULITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. VASCULITIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. VASCULITIS TREATMENT MARKET, FOR LARGE VESSEL VASCULITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. VASCULITIS TREATMENT MARKET FOR LARGE VESSEL VASCULITIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. GLOBAL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 15. VASCULITIS TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 16. VASCULITIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. VASCULITIS TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 18. VASCULITIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. VASCULITIS TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 20. VASCULITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. VASCULITIS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 22. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. U.S. VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. U.S. VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 29. U.S. VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. CANADA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. CANADA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 32. CANADA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. MEXICO VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 34. MEXICO VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 35. MEXICO VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 37. EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 38. EUROPE SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 39. EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. EUROPE VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 41. GERMANY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. GERMANY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 43. GERMANY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. FRANCE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 45. FRANCE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 46. FRANCE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. UK VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 48. UK VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 49. UK VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. ITALY VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 51. ITALY VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 52. ITALY VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 53. SPAIN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 54. SPAIN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 55. SPAIN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 56. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. REST OF EUROPE VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 61. ASIA-PACIFIC SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 64. JAPAN VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. JAPAN VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 66. JAPAN VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. CHINA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. CHINA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 69. CHINA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. INDIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 71. INDIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 72. INDIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 74. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 75. AUSTRALIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 76. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 77. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 82. LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 83. LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 84. LAMEA SMALL AND MEDIUM VESSEL VASCULITIS VASCULITIS TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. LAMEA VASCULITIS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 87. BRAZIL VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. BRAZIL VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 89. BRAZIL VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 91. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 92. SAUDI ARABIA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 94. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 95. SOUTH AFRICA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 96. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 97. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 98. REST OF LAMEA VASCULITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 99.AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 100.AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 101.AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 102.AMNEAL PHARMACEUTICALS, INC.: NET SALES,
TABLE 103.AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 104.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 105.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 106.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 107.ASTRAZENECA PLC: NET SALES,
TABLE 108.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 109.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 110.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 111.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 112.F. HOFFMANN-LA ROCHE LTD: NET SALES,
TABLE 113.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 114.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 115.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 116.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 117.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 118.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 119.PFIZER INC.: COMPANY SNAPSHOT
TABLE 120.PFIZER INC.: OPERATING SEGMENTS
TABLE 121.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 122.PFIZER INC.: NET SALES,
TABLE 123.PFIZER INC.: KEY STRATERGIES
TABLE 124.INFLARX N.V: COMPANY SNAPSHOT
TABLE 125.INFLARX N.V: OPERATING SEGMENTS
TABLE 126.INFLARX N.V: PRODUCT PORTFOLIO
TABLE 127.INFLARX N.V: NET SALES,
TABLE 128.INFLARX N.V: KEY STRATERGIES
TABLE 129.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 130.NOVARTIS AG: OPERATING SEGMENTS
TABLE 131.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 132.NOVARTIS AG: NET SALES,
TABLE 133.NOVARTIS AG: KEY STRATERGIES
TABLE 134.CHEMOCENTRYX: COMPANY SNAPSHOT
TABLE 135.CHEMOCENTRYX: OPERATING SEGMENTS
TABLE 136.CHEMOCENTRYX: PRODUCT PORTFOLIO
TABLE 137.CHEMOCENTRYX: NET SALES,
TABLE 138.CHEMOCENTRYX: KEY STRATERGIES
TABLE 139.ABBVIE: COMPANY SNAPSHOT
TABLE 140.ABBVIE: OPERATING SEGMENTS
TABLE 141.ABBVIE: PRODUCT PORTFOLIO
TABLE 142.ABBVIE: NET SALES,
TABLE 143.ABBVIE: KEY STRATERGIES
TABLE 144.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 145.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 146.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 147.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 148.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
